Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Axonal degeneration is responsible for disease progression and accumulation of disability in many neurodegenerative conditions. The axonal degenerative process can generate a metastable pool of damaged axons that remain structurally and functionally viable but fated to degenerate in the absence of external intervention. SARM1, an NADase that depletes axonal energy stores upon activation, is the central driver of an evolutionarily conserved program of axonal degeneration. We identify a potent and selective small molecule isoquinoline inhibitor of SARM1 NADase that recapitulates the SARM1 −/− phenotype and protects axons from degeneration induced by axotomy or mitochondrial dysfunction. SARM1 inhibition post-mitochondrial injury with rotenone allows recovery and rescues axons that already entered the metastable state. We conclude that SARM1 inhibition with small molecules has the potential to treat axonopathies of the central and peripheral nervous systems by preventing axonal degeneration and by allowing functional recovery of a metastable pool of damaged, but viable, axons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667 · cited 1×
“(O’Neill and Bowie, 2007), our findings, together with the complete protection afforded by the single point mutation E642A (Essuman et al.”
BackgroundCantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · cited 3×
“We further ruled out a role for participation of PARPs in the mechanism of isoquinoline axonal protection by showing that the potent dual PARP1 and PARP2 inhibitor olaparib did not contribute to axonal protection under the same assay conditions in which compound 5 and DSRM-3716 robustly prevented axonal degeneration.”
Axon degeneration mechanisms: Commonality amid diversity
Coleman, M. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1788 · Cited by 819 · cited 2×
“Notably, they displayed accumulation of cytoskeletal proteins β III-tubulin and neurofilaments, as well as NfH/SMI32 and β -APP, two markers of axonal damage and disrupted axonal transport (Trapp et al., 1998; Coleman, 2005).”
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713
SARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
Self-citationEndogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472 · cited 6×
“Although loss of NAD + from cut axons was not prevented completely by SARM1 inhibition, NAD + loss after axotomy results from the combined action of SARM1 activation, loss of synthetic ability because of fast turnover of remaining axonal NMNAT2 (Gilley and Coleman, 2010) (Figures S6A and S6B), and continuous use of NA…”
InfluentialNAD + Depletion Is Necessary and Sufficient forPoly(ADP-Ribose) Polymerase-1-Mediated Neuronal Death
Alano, C. C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T. M., & Swanson, R. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5552-09.2010 · Cited by 439 · cited 1×
“Although NAD + -consuming enzymes such as PARP (Cantó et al., 2015), can cause neuronal death (Alano et al., 2010), they do not participate in Wallerian or Wallerian-like degeneration (Gerdts et al., 2015; Sasaki et al., 2009) or in SARM1-dependent NAD + consumption (Essuman et al., 2017).”
A dual leucine kinase–dependent axon self-destruction program promotes Wallerian degeneration
Miller, B. R., Press, C., Daniels, R. W., Sasaki, Y., Milbrandt, J., & DiAntonio, A. (2009) · Nature Neuroscience · doi:10.1038/nn.2290 · Cited by 301
Self-citationRetrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272 · cited 1×
“…for, or substantially contributes to, disease progression, loss of function, and accumulation of disability in diseases as diverse as multiple sclerosis (Criste et al., 2014), Parkinson’s disease (Tagliaferro and Burke, 2016), and chemotherapy-induced peripheral neuropathy (Geisler et al., 2019).”
Cited by
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration
Figley, M. D., Gu, W., Nanson, J. D., Shi, Y., Sasaki, Y., Cunnea, K., Malde, A. K., Jia, X., Luo, Z., Saikot, F. K., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.009 · Cited by 324
Self-citationReducing acetylated tau is neuroprotective in brain injury
Shin, M.-K., Vázquez-Rosa, E., Koh, Y., Dhar, M., Chaubey, K., Cintrón-Pérez, C. J., Barker, S., Miller, E., Franke, K., Noterman, M. F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.032 · Cited by 226
Progressive axonopathy when oligodendrocytes lack the myelin protein CMTM5
Buscham, T. J., Eichel-Vogel, M. A., Steyer, A. M., Jahn, O., Strenzke, N., Dardawal, R., Memhave, T. R., Siems, S. B., Müller, C., Meschkat, M., et al. (2022) · eLife · doi:10.7554/elife.75523 · Cited by 18
SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy
Ding, C., Ndiaye, P. S., Campbell, S. R., Fry, M. Y., Gong, J., Wienbar, S. R., Gibbs, W., Morquette, P., Chao, L. H., Do, M. T. H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191315 · Cited by 8
Metadata
- Authors
- Hughes, R. O., Bosanac, T., Mao, X., Engber, T. M., DiAntonio, A., Milbrandt, J., Devraj, R., & Krauss, R.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 34
- Issue
- 1
- Pages
- 108588
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3119346562
- Cited by
- 185
- References
- 13
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. https://app.cochat.ai/papers/10.1016/j.celrep.2020.108588
- The paper
- Hughes, R. O., Bosanac, T., Mao, X., Engber, T. M., DiAntonio, A., Milbrandt, J., Devraj, R., & Krauss, R. (2021). Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. Cell Reports. https://doi.org/10.1016/j.celrep.2020.108588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.